Core Insights - The National Healthcare Security Administration and the National Health Commission of China have jointly released measures to support the high-quality development of innovative drugs, marking a shift from point support to a systematic empowerment of the entire innovation drug industry [1] - The policy coincides with an upward trend in internationalization, technological upgrades, and performance realization within the industry [1] - By Q1 2025, China has seen 41 foreign licensing transactions for innovative drugs, totaling $36.9 billion, nearing the total for the entire year of 2023 [1] - Chinese scholars contributed nearly 50% of global advancements in ADC antibodies and bispecific antibodies at the 2025 ASCO annual meeting, with 73 oral presentations [1] - Leading innovative drug companies are beginning to turn losses into profits, indicating a transition from a research investment phase to a performance realization phase [1] - The domestic innovative drug industry is expected to experience a turning point from capital-driven to profit-driven growth by 2025, presenting investment opportunities for both performance and valuation recovery [1] Industry Developments - The innovative drug ETF by Guotai (517110) tracks the CSI Hong Kong-Shenzhen Innovative Drug Industry Index, covering quality innovative drug companies across A-shares and Hong Kong Stock Connect, mitigating risks associated with single technology failures [2] - Investors interested in the innovative drug sector can consider the Guotai innovative drug ETF (517110) for a streamlined investment approach [2]
支持政策出台!创新药板块早盘持续领涨,创新药ETF国泰(517110)盘中涨超2.6%
Mei Ri Jing Ji Xin Wen·2025-07-03 05:31